Items where Author is "Ghulakhszian, A."
Article
Dinah, C. 
ORCID: 0000-0002-0815-4771, Enoch, J. ORCID: 0000-0002-4614-6676, Ghulakhszian, A. , Sekhon, M., Crabb, D. P. ORCID: 0000-0001-8611-1155 & Taylor, D. J. ORCID: 0000-0001-8261-5225 (2024).
Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study.
BMJ Open, 14(1),
article number e075713.
doi: 10.1136/bmjopen-2023-075713
Enoch, J. ORCID: 0000-0002-4614-6676, Ghulakhszian, A., Sekhon, M. , Crabb, D. P. ORCID: 0000-0001-8611-1155, Taylor, D. J. ORCID: 0000-0001-8261-5225 & Dinah, C. (2023).
Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: A mixed-methods study.
Eye, 37(17),
pp. 3634-3642.
doi: 10.1038/s41433-023-02571-3
Enoch, J. ORCID: 0000-0002-4614-6676, Ghulakhszian, A., Sekhon, M. , Crabb, D. P. ORCID: 0000-0001-8611-1155, Taylor, D. J. ORCID: 0000-0001-8261-5225 & Dinah, C. (2023).
Piloting a forced-choice task to elicit treatment preferences in geographic atrophy.
BMC Research Notes, 16(1),
article number 244.
doi: 10.1186/s13104-023-06531-8
Enoch, J. ORCID: 0000-0002-4614-6676, Ghulakhszian, A., Sekhon, M. , Crabb, D. P. ORCID: 0000-0001-8611-1155, Taylor, D. J. ORCID: 0000-0001-8261-5225 & Dinah, C. (2023).
Towards a Therapy for Geographic Atrophy: A Patient's Experience.
Patient Prefer Adherence, 17,
pp. 299-310.
doi: 10.2147/ppa.s386662
Dinah, C., Enoch, J. ORCID: 0000-0002-4614-6676, Ghulakhszian, A. , Taylor, D. J. ORCID: 0000-0001-8261-5225 & Crabb, D. P. ORCID: 0000-0001-8754-3902 (2022).
Intravitreal treatment for geographic atrophy: coming soon to a patient near you?.
Eye, 36(5),
pp. 1121-1123.
doi: 10.1038/s41433-021-01591-1
Enoch, J. ORCID: 0000-0002-4614-6676, Ghulakhszian, A., Crabb, D. P. ORCID: 0000-0001-8754-3902 , Dinah, C. & Taylor, D. J. ORCID: 0000-0001-8261-5225 (2021).
Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study.
BMJ Open, 11(4),
article number e049495.
doi: 10.1136/bmjopen-2021-049495
Sivaprasad, S., Vasconcelos, J. C., Prevost, A. T. , Holmes, H., Hykin, P., George, S., Murphy, C., Kelly, J., Arden, G. B., Ahfat, F., Bhatnagar, A., Narendran, N., Chavan, R., Cole, A., Crosby-Nwaobi, R., Patrao, N., Menon, D., Hogg, C., Rubin, G., Leitch-Devlin, L., Egan, C., Shah, N., Mansour, T., Peto, T., Eleftheriadis, H., Gibson, J., Ghulakhszian, A., Vafidis, G., Hughes, E., Jafree, A., Menon, G., Prakash, P., Sandinha, M., Smith, R., Scanlon, P., Chave, S., Aldington, S., Dale, A., Hood, G., Hitman, G. A., Crabb, D. P. ORCID: 0000-0001-8754-3902, Denniston, A., Lewin, D., Grierson, I., Walker, S., Sturt, J. & Sahu, D. (2018).
Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial.
The Lancet Diabetes and Endocrinology, 6(5),
pp. 382-391.
doi: 10.1016/s2213-8587(18)30036-6